Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Board Appointment

4 Sep 2017 07:00

RNS Number : 6139P
Ideagen PLC
04 September 2017
 

4 September 2017

Ideagen plc

 

("Ideagen" or the "Company")

 

Board Appointment

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, is pleased to announce the appointment of Tony Rodriguez to its board of directors as a non-executive director with immediate effect.

Mr Rodriguez, aged 48, is an experienced technology entrepreneur and software developer. After an early career in a number of blue-chip technology companies, he founded Avellino Technologies Ltd in 1997, and personally led the development of its data profiling software product, now known as TS Discovery, before its acquisition in 2004 by Harte Hanks Trillium. Subsequently he founded X88 Software, since acquired by Experian in 2014, where he led, as CEO and CTO, the development of its data management product (now known as Experian Pandora), which was recognised as a visionary by Gartner.

Jonathan Wearing, Chairman, commented that:

"We are delighted that Tony has agreed to join the Board. He brings to Ideagen a wealth of experience in successfully developing and commercialising market-leading software, which will be extremely helpful as we continue to drive forward the growth of the business."

Further information, as required pursuant to Schedule 2(g) of the AIM Rules for Companies, are set out below.

Current directorships and/or partnerships:

Former directorships and/or partnerships (within the last five years):

X88 Limited

X88 Software Limited

Tony Rodriguez Limited

There are no further disclosures required under Schedule 2(g) of the AIM Rules for Companies.

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Enquiries:

Ideagen plc

Tel: 01629 699100

David Hornsby, Chief Executive

Graeme Spenceley, Finance Director

finnCap (Nominated Adviser and Broker)

Tel: 020 7220 0500

Stuart Andrews / James Thompson (Corporate Finance)

Stephen Norcross (Corporate Broking)

 

About Ideagen plc

Ideagen is a UK company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

Ideagen is a supplier of Information Management software with operations in the UK, the United States and the Middle East. The Company specialises in GRC (Governance, Risk and Compliance) and Content and Clinical solutions with a primary focus on organisations operating within highly regulated industries. With an excellent portfolio of software products, Ideagen is able to provide complete information lifecycle solutions that enable organisations to reduce risk, meet their regulatory and compliance standards, helping them to reduce costs and improve efficiency.

The Group has a customer base of over 3,000 organisations using the Ideagen suite of products, including many blue chip names such as BAE Systems, Emirates, Shell and the European Central Bank as well as 150 hospitals in the UK and US.

For further information please visit www.ideagen.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAUGUQGBUPMGPG
Date   Source Headline
20th Apr 20221:01 pmGNWForm 8.3 - [Ideagen plc - 19 04 2022] - (HHL)
20th Apr 202212:58 pmGNWForm 8.3 - [Ideagen plc - 19 04 2022] - (CGWL)
20th Apr 202212:54 pmRNSForm 8.3 - Ideagen plc
20th Apr 202212:34 pmRNSForm 8.3 - Ideagen Plc
20th Apr 202212:28 pmRNSForm 8.3 - Ideagen PLC
20th Apr 202211:56 amBUSForm 8.3 - Ideagen Plc
20th Apr 202211:38 amRNSForm 8.5 (EPT/RI)
20th Apr 202211:11 amRNSForm 8 (DD) - Ideagen Plc
20th Apr 202210:52 amGNWForm 8.3 - Ideagen
20th Apr 202210:42 amGNWForm 8.3 - Ideagen Plc
20th Apr 20229:34 amRNSForm 8.5 (EPT/RI) - Ideagen Plc
20th Apr 20229:11 amRNSForm 8.5 (EPT/RI)
19th Apr 20225:44 pmBUSForm 8.3 - Ideagen PLC
19th Apr 20225:28 pmRNSForm 8.3 - Ideagen PLC
19th Apr 20225:19 pmRNSForm 8.3 - Ideagen plc
19th Apr 20221:32 pmRNSForm 8.3 - Ideagen PLC
19th Apr 20227:00 amRNSResponse to Cinven Statement
14th Apr 20225:26 pmRNSPossible Offer for Ideagen PLC
13th Apr 202212:00 pmRNSIssue of shares, Director/PDMR Shareholding & TVR
8th Apr 202212:30 pmRNSExercise of Options and Total Voting Rights
1st Apr 20227:00 amRNSTotal Voting Rights
25th Mar 20226:00 pmRNSDirector/PDMR Shareholding
14th Mar 20227:00 amRNSIssue of Equity and TVR
1st Mar 20222:35 pmRNSDirector/PDMR Shareholding
1st Mar 20222:30 pmRNSTotal Voting Rights
11th Feb 20225:45 pmRNSIssue of Shares under SIP and TVR
11th Feb 202211:01 amRNSHolding(s) in Company
9th Feb 20227:01 amRNSAcquisition of MailManager
9th Feb 20227:00 amRNSChange of Adviser
1st Feb 20228:30 amRNSTotal Voting Rights
13th Jan 20227:01 amRNSGrant of awards under the Ideagen LTIP
13th Jan 20227:00 amRNSUnaudited Interim Results
12th Jan 202212:02 pmRNSIssue of Shares Under SIP and Total Voting Rights
4th Jan 20222:45 pmRNSTotal Voting Rights
14th Dec 20214:30 pmRNSIssue of Shares Under SIP and Total Voting Rights
13th Dec 20216:00 pmRNSHolding(s) in Company
9th Dec 20219:05 amRNSSecond Price Monitoring Extn
9th Dec 20219:00 amRNSPrice Monitoring Extension
9th Dec 20217:00 amRNSResult of Placing and PrimaryBid Offer
8th Dec 20214:50 pmRNSRetail Offer by PrimaryBid
8th Dec 20214:49 pmRNSProposed Placing of Ordinary Shares
1st Dec 20214:15 pmRNSTotal Voting Rights
30th Nov 20217:00 amRNSCapital Markets Day
15th Nov 20217:00 amRNSHalf Year Trading Update and Acquisition
12th Nov 20214:46 pmRNSIssue of new shares under the SIP and TVR
9th Nov 20217:00 amRNSAcquisition of CompliSpace
1st Nov 202111:52 amRNSTotal Voting Rights
28th Oct 20215:30 pmRNSResult of AGM
27th Oct 20217:00 amRNSAcquisitions of Audit Analytics and Ai XPRT
22nd Oct 20217:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.